

NUMBER OF SHARES AND VOTES IN CINCLUS PHARMA

The number of shares and votes in Cinclus Pharma Holding AB (publ) ("Cinclus Pharma") has changed as a result of the share issues carried out in connection with the listing of Cinclus Pharma's ordinary shares on Nasdaq Stockholm on 20 June 2024.

Through the new share issues, the number of shares and votes has increased by 20,310,749, from 26,227,040 to 46,537,789 shares and votes. The share capital has increased by approximately SEK 394,298, from SEK 509,153 to approximately SEK 903,451.

This information is information that Cinclus Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-06-28 08:45 CEST.

For additional information, please contact:

Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com

Charlotte Stjerngren, IR
Phone: +46 70 876 87 87
e-mail: charlotte.stjerngren@cincluspharma.com

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a clinical stage pharma company developing a molecule for the treatment of gastric acid-related diseases and *H. pylori* infection. Its drug candidate linaprazan glurate represents a novel class of drugs, Potassium-Competitive Acid Blockers (P#CAB), and provides a fast-acting control of intragastric pH by a different mechanism of action than proton pump inhibitors (PPIs). For more information, please visit www.cincluspharma.com.

Attachments

Number of shares and votes in Cinclus Pharma